Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79


Defining a murine ovarian cancer model for the evaluation of conditionally-replicative adenovirus (CRAd) virotherapy agents.

González-Pastor R, Ashshi AM, El-Shemi AG, Dmitriev IP, Kashentseva EA, Lu ZH, Goedegebuure SP, Podhajcer OL, Curiel DT.

J Ovarian Res. 2019 Feb 15;12(1):18. doi: 10.1186/s13048-019-0493-5.


Application of Synthetic Tumor-Specific Promoters Responsive to the Tumor Microenvironment.

Cafferata EG, Lopez MV, Nuñez FJ, Maenza MAR, Podhajcer OL.

Methods Mol Biol. 2017;1651:213-227. doi: 10.1007/978-1-4939-7223-4_16.


Synthetic Tumor-Specific Promoters for Transcriptional Regulation of Viral Replication.

Lopez MV, Cafferata EG, Viale DL, Podhajcer OL.

Methods Mol Biol. 2017;1651:113-130. doi: 10.1007/978-1-4939-7223-4_9.


Oncolytic Adenovirus-Loaded Menstrual Blood Stem Cells Overcome the Blockade of Viral Activity Exerted by Ovarian Cancer Ascites.

Alfano AL, Nicola Candia A, Cuneo N, Guttlein LN, Soderini A, Rotondaro C, Sganga L, Podhajcer OL, Lopez MV.

Mol Ther Oncolytics. 2017 Jun 16;6:31-44. doi: 10.1016/j.omto.2017.06.002. eCollection 2017 Sep 15.


TarSeqQC: Quality control on targeted sequencing experiments in R.

Merino GA, Murua YA, Fresno C, Sendoya JM, Golubicki M, Iseas S, Coraglio M, Podhajcer OL, Llera AS, Fernández EA.

Hum Mutat. 2017 May;38(5):494-502. doi: 10.1002/humu.23204. Epub 2017 Mar 21.


A novel non-parametric method for uncertainty evaluation of correlation-based molecular signatures: its application on PAM50 algorithm.

Fresno C, González GA, Merino GA, Flesia AG, Podhajcer OL, Llera AS, Fernández EA.

Bioinformatics. 2017 Mar 1;33(5):693-700. doi: 10.1093/bioinformatics/btw704.


Predictive Outcomes for HER2-enriched Cancer Using Growth and Metastasis Signatures Driven By SPARC.

Güttlein LN, Benedetti LG, Fresno C, Spallanzani RG, Mansilla SF, Rotondaro C, Raffo Iraolagoitia XL, Salvatierra E, Bravo AI, Fernández EA, Gottifredi V, Zwirner NW, Llera AS, Podhajcer OL.

Mol Cancer Res. 2017 Mar;15(3):304-316. doi: 10.1158/1541-7786.MCR-16-0243-T. Epub 2016 Dec 28.


SPARC Controls Melanoma Cell Plasticity through Rac1.

Salvatierra E, Alvarez MJ, Leishman CC, Rivas Baquero E, Lutzky VP, Chuluyan HE, Podhajcer OL.

PLoS One. 2015 Aug 6;10(8):e0134714. doi: 10.1371/journal.pone.0134714. eCollection 2015.


Cytokine-enhanced maturation and migration to the lymph nodes of a human dying melanoma cell-loaded dendritic cell vaccine.

Pizzurro GA, Tapia IJ, Sganga L, Podhajcer OL, Mordoh J, Barrio MM.

Cancer Immunol Immunother. 2015 Nov;64(11):1393-406. doi: 10.1007/s00262-015-1743-z. Epub 2015 Jul 22.


Personalized virotherapy in cancer.

Cafferata EG, Podhajcer OL.

Aging (Albany NY). 2015 May;7(5):288-9. No abstract available.


A Novel CDC25B Promoter-Based Oncolytic Adenovirus Inhibited Growth of Orthotopic Human Pancreatic Tumors in Different Preclinical Models.

Weber HL, Gidekel M, Werbajh S, Salvatierra E, Rotondaro C, Sganga L, Haab GA, Curiel DT, Cafferata EG, Podhajcer OL.

Clin Cancer Res. 2015 Apr 1;21(7):1665-74. doi: 10.1158/1078-0432.CCR-14-2316. Epub 2015 Jan 8.


Current status of stem cells and regenerative medicine research in Argentina.

Pitossi FJ, Podhajcer OL.

Stem Cells Dev. 2014 Dec;23 Suppl 1:17-9. doi: 10.1089/scd.2014.0403.


Amyloid peptides ABri and ADan show differential neurotoxicity in transgenic Drosophila models of familial British and Danish dementia.

Marcora MS, Fernández-Gamba AC, Avendaño LA, Rotondaro C, Podhajcer OL, Vidal R, Morelli L, Ceriani MF, Castaño EM.

Mol Neurodegener. 2014 Jan 9;9:5. doi: 10.1186/1750-1326-9-5.


The low-abundance transcriptome reveals novel biomarkers, specific intracellular pathways and targetable genes associated with advanced gastric cancer.

Bizama C, Benavente F, Salvatierra E, Gutiérrez-Moraga A, Espinoza JA, Fernández EA, Roa I, Mazzolini G, Sagredo EA, Gidekel M, Podhajcer OL.

Int J Cancer. 2014 Feb 15;134(4):755-64. doi: 10.1002/ijc.28405. Epub 2013 Aug 29.


Enhanced CRAd activity using enhancer motifs driven by a nucleosome positioning sequence.

Bravo S, Núñez F, Cruzat F, Cafferata EG, De Ferrari GV, Montecino M, Podhajcer OL.

Mol Ther. 2013 Jul;21(7):1403-12. doi: 10.1038/mt.2013.93. Epub 2013 May 28.


Therapeutic improvement of a stroma-targeted CRAd by incorporating motives responsive to the melanoma microenvironment.

Viale DL, Cafferata EG, Gould D, Rotondaro C, Chernajovsky Y, Curiel DT, Podhajcer OL, Veronica Lopez M.

J Invest Dermatol. 2013 Nov;133(11):2576-2584. doi: 10.1038/jid.2013.191. Epub 2013 Apr 19.


Hippocampal SPARC regulates depression-related behavior.

Campolongo M, Benedetti L, Podhajcer OL, Pitossi F, Depino AM.

Genes Brain Behav. 2012 Nov;11(8):966-76. doi: 10.1111/j.1601-183X.2012.00848.x. Epub 2012 Sep 27.


A tumor-stroma targeted oncolytic adenovirus replicated in human ovary cancer samples and inhibited growth of disseminated solid tumors in mice.

Lopez MV, Rivera AA, Viale DL, Benedetti L, Cuneo N, Kimball KJ, Wang M, Douglas JT, Zhu ZB, Bravo AI, Gidekel M, Alvarez RD, Curiel DT, Podhajcer OL.

Mol Ther. 2012 Dec;20(12):2222-33. doi: 10.1038/mt.2012.147. Epub 2012 Sep 4.


The tumor microenvironment: characterization, redox considerations, and novel approaches for reactive oxygen species-targeted gene therapy.

Policastro LL, Ibañez IL, Notcovich C, Duran HA, Podhajcer OL.

Antioxid Redox Signal. 2013 Sep 10;19(8):854-95. doi: 10.1089/ars.2011.4367. Epub 2012 Oct 2. Review.


A specific subpopulation of mesenchymal stromal cell carriers overrides melanoma resistance to an oncolytic adenovirus.

Bolontrade MF, Sganga L, Piaggio E, Viale DL, Sorrentino MA, Robinson A, Sevlever G, García MG, Mazzolini G, Podhajcer OL.

Stem Cells Dev. 2012 Sep 20;21(14):2689-702. doi: 10.1089/scd.2011.0643. Epub 2012 May 14.


The multi-reference contrast method: facilitating set enrichment analysis.

Fresno C, Llera AS, Girotti MR, Valacco MP, López JA, Podhajcer OL, Balzarini MG, Prada F, Fernández EA.

Comput Biol Med. 2012 Feb;42(2):188-94. doi: 10.1016/j.compbiomed.2011.11.007. Epub 2012 Jan 9.


A novel hybrid promoter responsive to pathophysiological and pharmacological regulation.

Subang MC, Fatah R, Bright C, Blanco P, Berenstein M, Wu Y, Podhajcer OL, Winyard PG, Chernajovsky Y, Gould D.

J Mol Med (Berl). 2012 Apr;90(4):401-11. doi: 10.1007/s00109-011-0826-3. Epub 2011 Oct 30.


SPARC promotes cathepsin B-mediated melanoma invasiveness through a collagen I/α2β1 integrin axis.

Girotti MR, Fernández M, López JA, Camafeita E, Fernández EA, Albar JP, Benedetti LG, Valacco MP, Brekken RA, Podhajcer OL, Llera AS.

J Invest Dermatol. 2011 Dec;131(12):2438-47. doi: 10.1038/jid.2011.239. Epub 2011 Aug 18.


Mesenchymal stem cells as therapeutic tools and gene carriers in liver fibrosis and hepatocellular carcinoma.

Aquino JB, Bolontrade MF, García MG, Podhajcer OL, Mazzolini G.

Gene Ther. 2010 Jun;17(6):692-708. doi: 10.1038/gt.2010.10. Epub 2010 Mar 11. Review.


Stem cell research in South America coming of age.

Podhajcer OL, Miriuka S.

Cell Stem Cell. 2010 Mar 5;6(3):209-13. doi: 10.1016/j.stem.2010.02.008.


Matricellular proteins and inflammatory cells: a task force to promote or defeat cancer?

Llera AS, Girotti MR, Benedetti LG, Podhajcer OL.

Cytokine Growth Factor Rev. 2010 Feb;21(1):67-76. doi: 10.1016/j.cytogfr.2009.11.010. Epub 2009 Dec 16. Review.


Overexpression of SPARC obliterates the in vivo tumorigenicity of human hepatocellular carcinoma cells.

Atorrasagasti C, Malvicini M, Aquino JB, Alaniz L, Garcia M, Bolontrade M, Rizzo M, Podhajcer OL, Mazzolini G.

Int J Cancer. 2010 Jun 1;126(11):2726-40. doi: 10.1002/ijc.24966.


Suppression of cancer growth by nonviral gene therapy based on a novel reactive oxygen species-responsive promoter.

Policastro LL, Ibañez IL, Durán HA, Soria G, Gottifredi V, Podhajcer OL.

Mol Ther. 2009 Aug;17(8):1355-64. doi: 10.1038/mt.2009.103. Epub 2009 May 12.


Tumor associated stromal cells play a critical role on the outcome of the oncolytic efficacy of conditionally replicative adenoviruses.

Lopez MV, Viale DL, Cafferata EG, Bravo AI, Carbone C, Gould D, Chernajovsky Y, Podhajcer OL.

PLoS One. 2009;4(4):e5119. doi: 10.1371/journal.pone.0005119. Epub 2008 Apr 8.


A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models.

Cafferata EG, Macció DR, Lopez MV, Viale DL, Carbone C, Mazzolini G, Podhajcer OL.

Clin Cancer Res. 2009 May 1;15(9):3037-49. doi: 10.1158/1078-0432.CCR-08-1161. Epub 2009 Mar 31.


Improving 2D-DIGE protein expression analysis by two-stage linear mixed models: assessing experimental effects in a melanoma cell study.

Fernández EA, Girotti MR, López del Olmo JA, Llera AS, Podhajcer OL, Cantet RJ, Balzarini M.

Bioinformatics. 2008 Dec 1;24(23):2706-12. doi: 10.1093/bioinformatics/btn508. Epub 2008 Sep 25.


p21 differentially regulates DNA replication and DNA-repair-associated processes after UV irradiation.

Soria G, Speroni J, Podhajcer OL, Prives C, Gottifredi V.

J Cell Sci. 2008 Oct 1;121(Pt 19):3271-82. doi: 10.1242/jcs.027730. Epub 2008 Sep 9.


Adenovirus-mediated inhibition of SPARC attenuates liver fibrosis in rats.

Camino AM, Atorrasagasti C, Maccio D, Prada F, Salvatierra E, Rizzo M, Alaniz L, Aquino JB, Podhajcer OL, Silva M, Mazzolini G.

J Gene Med. 2008 Sep;10(9):993-1004. doi: 10.1002/jgm.1228.


Silencing survivin gene expression promotes apoptosis of human breast cancer cells through a caspase-independent pathway.

Croci DO, Cogno IS, Vittar NB, Salvatierra E, Trajtenberg F, Podhajcer OL, Osinaga E, Rabinovich GA, Rivarola VA.

J Cell Biochem. 2008 Oct 1;105(2):381-90. doi: 10.1002/jcb.21836.


The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host.

Podhajcer OL, Benedetti LG, Girotti MR, Prada F, Salvatierra E, Llera AS.

Cancer Metastasis Rev. 2008 Dec;27(4):691-705. doi: 10.1007/s10555-008-9146-7. Review.


The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host.

Podhajcer OL, Benedetti L, Girotti MR, Prada F, Salvatierra E, Llera AS.

Cancer Metastasis Rev. 2008 Sep;27(3):523-37. doi: 10.1007/s10555-008-9135-x. Review.


SPARC modulates the proliferation of stromal but not melanoma cells unless endogenous SPARC expression is downregulated.

Haber CL, Gottifredi V, Llera AS, Salvatierra E, Prada F, Alonso L, Sage EH, Podhajcer OL.

Int J Cancer. 2008 Apr 1;122(7):1465-75. Erratum in: Int J Cancer. 2008 Jul 1;123(1):245. Helene, Sage E [corrected to Sage, E Helene].


Proteomic analysis identified N-cadherin, clusterin, and HSP27 as mediators of SPARC (secreted protein, acidic and rich in cysteines) activity in melanoma cells.

Sosa MS, Girotti MR, Salvatierra E, Prada F, de Olmo JA, Gallango SJ, Albar JP, Podhajcer OL, Llera AS.

Proteomics. 2007 Nov;7(22):4123-34.


SPARC endogenous level, rather than fibroblast-produced SPARC or stroma reorganization induced by SPARC, is responsible for melanoma cell growth.

Prada F, Benedetti LG, Bravo AI, Alvarez MJ, Carbone C, Podhajcer OL.

J Invest Dermatol. 2007 Nov;127(11):2618-28. Epub 2007 Jul 12.


Model based analysis of real-time PCR data from DNA binding dye protocols.

Alvarez MJ, Vila-Ortiz GJ, Salibe MC, Podhajcer OL, Pitossi FJ.

BMC Bioinformatics. 2007 Mar 9;8:85.


Cytokine gene transfer for cancer therapy.

Podhajcer OL, Lopez MV, Mazzolini G.

Cytokine Growth Factor Rev. 2007 Feb-Apr;18(1-2):183-94. Epub 2007 Feb 21. Review.


Expression of a suicidal gene under control of the human secreted protein acidic and rich in cysteine (SPARC) promoter in tumor or stromal cells led to the inhibition of tumor cell growth.

Lopez MV, Blanco P, Viale DL, Cafferata EG, Carbone C, Gould D, Chernajovsky Y, Podhajcer OL.

Mol Cancer Ther. 2006 Oct;5(10):2503-11.


Platelet-endothelial cell adhesion molecule-1 (CD31) recycles and induces cell growth inhibition on human tumor cell lines.

Lutzky VP, Carnevale RP, Alvarez MJ, Maffia PC, Zittermann SI, Podhajcer OL, Issekutz AC, Chuluyan HE.

J Cell Biochem. 2006 Aug 1;98(5):1334-50.


IL-12 and IL-10 expression synergize to induce the immune-mediated eradication of established colon and mammary tumors and lung metastasis.

Lopez MV, Adris SK, Bravo AI, Chernajovsky Y, Podhajcer OL.

J Immunol. 2005 Nov 1;175(9):5885-94.


Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity.

Alvarez MJ, Prada F, Salvatierra E, Bravo AI, Lutzky VP, Carbone C, Pitossi FJ, Chuluyan HE, Podhajcer OL.

Cancer Res. 2005 Jun 15;65(12):5123-32.


Gene therapy for autoimmune diseases: quo vadis?

Chernajovsky Y, Gould DJ, Podhajcer OL.

Nat Rev Immunol. 2004 Oct;4(10):800-11. Review.


International Hermelin brain tumor symposium on matricellular proteins in normal and cancer cell-matrix interactions.

Bos TJ, Cohn SL, Kleinman HK, Murphy-Ulrich JE, Podhajcer OL, Rempel SA, Rich JN, Rutka JT, Sage EH, Thompson EW.

Matrix Biol. 2004 Apr;23(1):63-9. No abstract available.


Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege.

Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, Mordoh J, Fainboim L, Podhajcer OL, Rabinovich GA.

Cancer Cell. 2004 Mar;5(3):241-51.


Imbalance of antioxidant enzymes in tumor cells and inhibition of proliferation and malignant features by scavenging hydrogen peroxide.

Policastro L, Molinari B, Larcher F, Blanco P, Podhajcer OL, Costa CS, Rojas P, Durán H.

Mol Carcinog. 2004 Feb;39(2):103-13.


A novel doxycycline inducible autoregulatory plasmid which displays "on"/"off" regulation suited to gene therapy applications.

Gould DJ, Berenstein M, Dreja H, Ledda F, Podhajcer OL, Chernajovsky Y.

Gene Ther. 2000 Dec;7(24):2061-70.

Supplemental Content

Loading ...
Support Center